Nkarta
NKTX | NASDAQ
$1.21
+$0.02 (+1.68%)
At close: Nov 16, 2026, 4:00 PM ET
$1.21
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+1.68%
(1D)No price chart data available for 1D timeframe.
Rating
29.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #816/1021 (Top 80%)
Key Statistics
Market Data
Market Cap $86.67M
1D Range
1.20 1.28
52W Range
1.19 3.67
Valuation (TTM)
PE -0.70
PB 0.40
EV/EBITDA -0.02
Valuation (NTM)
Forward PE N/A
Forward PEG -0.02
Price Target $9.00
Cash Flow
FCF Yield -118.0%
SBC Adj. FCF Yield -126.6%
SBC Impact -7.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 4.5% |
14.6%
FCF 3Y | 5Y 3.0% |
-1.1%
Returns
ROA -41.8%
ROE -48.6%
ROIC -48.9%
Financial Health
Net Cash
$84.57M
Current Ratio 5.79
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a...
Sector Healthcare
Industry Biotechnology
Employees 106
IPO Date Jul 10, 2020
Website www.nkartatx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$9.00
Upside
+643.80%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NKTX